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Abstract
Huntington’s disease is a dominantly inherited neurodegenerative disease caused by the expansion of a CAG repeat in the
HTT gene. In addition to the length of the CAG expansion, factors such as genetic background have been shown to contribute
to the age at onset of neurological symptoms. A central challenge in understanding the disease progression that leads from
the HD mutation to massive cell death in the striatum is the ability to characterize the subtle and early functional
consequences of the CAG expansion longitudinally. We used dense time course sampling between 4 and 20 postnatal weeks
to characterize early transcriptomic, molecular and cellular phenotypes in the striatum of six distinct knock-in mouse models of the HD mutation. We studied the effects of the HttQ111 allele on the C57BL/6J, CD-1, FVB/NCr1, and 129S2/SvPasCrl genetic backgrounds, and of two additional alleles, HttQ92 and HttQ50, on the C57BL/6J background. We describe the emergence of
a transcriptomic signature in HttQ111/þ mice involving hundreds of differentially expressed genes and changes in diverse
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molecular pathways. We also show that this time course spanned the onset of mutant huntingtin nuclear localization phenotypes and somatic CAG-length instability in the striatum. Genetic background strongly influenced the magnitude and age at
onset of these effects. This work provides a foundation for understanding the earliest transcriptional and molecular changes
contributing to HD pathogenesis.

Introduction
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder that is characterized by progressive motor
impairments, accompanied by cognitive impairment and psychiatric symptoms, leading to premature death (1). HD is caused
by an expanded CAG trinucleotide repeat in the HTT gene,
encoding an elongated polyglutamine (polyQ) tract in the huntingtin protein (2).
The age at onset of HD symptoms ranges from rare juvenile
cases to more typical onset in mid- to late-adulthood. Rare, longer CAG lengths (>60) lead to juvenile onset (3–5) whereas 40–50
CAG repeats is typical of adult onset disease. Approximately
66% of variation in age at onset for adult CAG ranges (40–53
CAGs) is explained by an inverse relationship with the length of
the expanded CAG tract (6). Genetic modifiers of age at onset at
other genomic loci explain some of the remaining variance,
with loci on chromosomes 8 and 15 reaching genome-wide significance in a recent genome-wide association study (7).
Environmental and lifestyle factors may also contribute to variation in the age at onset.
Neuropathological studies of HD have revealed specific loss
of GABAergic medium spiny projection neurons in the striatum
(8) that occurs earlier and is more profound than cell death in
other brain regions. It is thought that this loss of medium spiny
neurons explains many of the symptoms of HD. Mouse models
have revealed a wide range of molecular and cellular pathology
in the striatum preceding cell death, including synaptic dysfunction (9), neuroinflammation (10), altered cholesterol and
energy metabolism (11,12), and changes in chromatin structure
(13). Many of these phenotypes were originally discovered
through gene expression profiling, which revealed thousands of
differentially expressed genes in both post-mortem striatal tissue from HD patients and in mouse models of HD (14–16).
Here, we describe large-scale gene expression profiling and
molecular phenotyping of striatal tissue from six distinct knockin mouse models of HD during a time course from 4 to 20 postnatal weeks. Our study included the HttQ111 allele on the C57BL/6J,
CD-1, FVB/NCr1, and 129S2/SvPasCrl genetic backgrounds and
two additional shorter CAG repeat alleles (HttQ92 and HttQ50) on
the C57BL/6J background. Some behavioral changes have been
observed in HttQ111 mice at 11–12 weeks of age as well as memory
deficits at 16 weeks of age (17,18). But motor phenotypes were not
seen in HttQ111 mice until 9 months of age (19). Overall, our longitudinal study likely encompasses some behavioral and cognitive
changes, but no clear motor deficits.
The goals of our study were two-fold. First, we aimed to
identify very early events in the progression of molecular and
cellular phenotypes underlying HD. Identifying early events in
the progression of the disease is critical, since these changes
are likely to be enriched for causal mechanisms. By contrast,
most previous gene expression profiling experiments and similar studies in HD mouse models have focused on the later stages
of the disease progression or sampled at low density time
points that do not capture early inflection points (15,16,20).
Second, we aimed to characterize similarities and differences in the effects of Htt CAG expansion when occurring on

different genetic backgrounds. Given the now strong evidence
for genetic modifiers in the human disease, modeling the effect
of genetic variation in mice is an increasingly high priority. In
addition, identifying changes that are robust across multiple genetic backgrounds is a proven strategy to improve signal-tonoise and eliminate false positive results (21).
Here, we find a cascade of gene expression changes associated with Htt CAG expansion beginning in mice as young as 10–
16-week old. We show that this time course spanned the onset
of two known early molecular phenotypes in HD mouse models:
nuclear localization of the mutant huntingtin protein and
striatal CAG-length genomic instability. Genetic background
strongly influenced the rate at which molecular and transcriptomic phenotypes emerged, suggesting the presence of multiple
genetic modifiers, and emphasizing the importance of studying
human disease in model systems that account for genetic
variation.

Results
Experimental design
In view of the dominant nature of HD, we used heterozygous
knock-in mouse lines in which expanded CAG repeats of various lengths have been inserted into one of the mouse’s endogenous Htt alleles (Fig. 1A). The HttQ111 allele (previously HdhQ111;
‘Q111’) has been backcrossed onto four different genetic strain
backgrounds: C57BL/6J (‘B6’), CD-1, FVB/NCrl (‘FVB’), and 129S2/
SvPasCrl (‘129’) (22–24). On the B6 background, we also characterized knock-in mice carrying shorter alleles, HttQ50 (‘Q50’) and
HttQ92 (‘Q92’) (16,24,25). Note that Q111, Q92 and Q50 are the
nominal allele names, but due to intergenerational instability in
Q92 and Q111 that is background strain-dependent (23,24), mice
from these lines vary in their actual CAG repeat length (Fig. 1B).
Siblings of these knock-in mice that did not carry pathogenic alleles (‘WT’) were used as controls. Three mice of each genotype
were collected each week between 4 and 20 postnatal weeks,
and an additional ten mice were collected every fourth week for
the B6.Q50, B6.Q111 and CD-1.Q111 lines. 2–10 mice per week
from each genotype were used for gene expression profiling and
for cellular and molecular phenotyping (Fig. 1A; Supplementary
Material, Table S1).
We measured the body mass and brain mass of each mouse.
Age and strain influenced these traits, but there were no statistically significant differences in body mass or brain mass associated with Htt alleles (Supplementary Materials, Tables S2 and S3).

Dynamic huntingtin nuclear localization patterns across
strain and over time
Nuclear localization of mutant huntingtin protein (mHTT) is
one of the earliest known molecular phenotypes in HD knock-in
mouse models (26). We measured nuclear huntingtin immunostaining phenotypes in the striata of 84 Q111 mice, using a
conformation-specific antibody that recognizes forms of mHTT
in the nuclei of striatal medium spiny neurons (Fig. 1C and D)
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(26,27). Diffuse nuclear mHTT immunostaining was visible in a
fraction of striatal cells in heterozygous B6.Q111, CD-1.Q111,
and FVB.Q111 mice as young as 9- to 10-week old (Fig. 1D). In
these strains, the intensity of nuclear staining increased over
time (ANOVA, Page ¼ 1.5e-5; Fig. 1D). By 20 weeks, diffuse nuclear
mHTT was prominent in striatal neurons in these strains (Fig.
1C). Punctate nuclear mHTT inclusions were visible in these
strains beginning at 17 weeks. In contrast to the other three
strains, diffuse nuclear huntingtin was not visible in the
129.Q111 mice until they were at least 15 weeks old and was not
as intense as in the other three strains (ANOVA: Pstrain ¼ 1.1e-3).
Punctate nuclear inclusions were not observed in 129.Q111 mice
up to 20 weeks of age. These strain differences are consistent with the relative timing of nuclear localization and inclusion formation in previous observations in these strains
(23,26,28).

Somatic CAG length expansion in striatum
across strain and over time
We profiled the distribution of Htt CAG lengths in striatal tissue from Q111 mice (n ¼ 250). Previous studies showed that genetic differences between B6.Q111, 129.Q111 and FVB.Q111
mice influence the rate of striatal CAG length expansion
(23,29). While repeat expansion dynamics have been analyzed
in CD-1.Q111 mice over a broad (2–16 months) time window
(22), very early repeat expansion dynamics and the relationship to molecular phenotypes are not well established. We observed age- and strain-dependent effects on the extent of
striatal CAG length instability (Fig. 1E). The ‘instability index’
summarizes the mean change in CAG repeat length observed
in each mouse’s striatum. Instability index increased as a linear function of age in all four strains, but the rate of instability
differed. Consistent with previous results (23,29), CAG tracts
expanded more extensively in B6.Q111 and FVB.Q111 mice
than in 129.Q111 heterozygous mice. The rates of CAG tract expansion in CD-1.Q111 mice were roughly similar to those in
FVB.Q111 mice, but CD-1.Q111 exhibited greater variation in
instability indices, consistent with this being an outbred
strain.

Differentially expressed genes in 4- to 20-week-old
knock-in mouse models of the HD mutation
Figure 1. Time course of mHTT nuclear localization and of striatal Htt CAG
length expansion in 4- to 20-week-old HD knock-in mice. (A) Striatal tissue was
collected from a total of 731 4- to 20-week-old mice in order to compare mice
with heterozygous mutant Htt alleles (Q111, Q92, Q50) to mice with wild-type Htt
alleles (WT) on four genetic backgrounds. (B) Inherited CAG repeat length of Htt
alleles in HttQ111 mice varies with genetic background. The CAG repeat length in
each mouse with a nominal HttQ111 allele was measured in a tail snip sample at
weaning. (C) Nuclear mutant huntingtin immunofluorescence using mAb5374
(red) and DAPI (blue) counterstain in 20-week-old B6.Q111, CD1.Q111, FVB.Q111,
129.Q111 mice, along with negative control 20 week-old B6.WT. All images were
acquired at the same sensitivity and displayed with equal adjustment of the levels to enhance the red signal relative to background and nuclear staining. To illustrate the pattern of the weak staining in 129.Q111 the cell in the inset was
further enhanced; arrows indicate positive cells. The white scale bar represents
10 mm. (D) Quantitation of mHtt immunofluorescence intensity in 9- to 20-weekold Q111 mice from each background (n ¼ 84 total mice, n ¼ 20–25 mice per
strain). Each point indicates the immunofluorescence intensity in a single cell.
(E). Age- and background strain-dependent expansion of Htt CAG tracts in the
striata of 4- to 20-week-old Q111 mice. Each point represents the ‘instability index’ for a single mouse, a quantitative metric representing the mean CAG length
change in the population, relative to the modal allele.

We used linear modeling to characterize gene expression
changes in each HD mouse model. We considered 18 conditions,
defined by a mouse’s genotype and age. For each of the six genetically distinct HD mouse models—B6.Q111, CD-1.Q111,
FVB.Q111, 129.Q111, B6.Q92, and B6.Q50—we considered three
non-overlapping age windows with equal numbers of mice:
‘early’, 4-9 postnatal weeks; ‘middle’, 9–16 postnatal weeks; and
‘late’, 16–20 postnatal weeks. We compared these mice to agematched wildtype mice of the same strain. In the early age window, we detected fewer than 25 differentially expressed genes
(DEGs, q < 0.05) in all mouse models (Fig. 2A). In the middle age
window, we detected 279 DEGs in B6.Q111 mice and < 25 DEGs
in the other mouse models. In the late age window, we detected
1,513 DEGs in B6.Q111 mice, 222 DEGs in CD-1.Q111 mice,
and < 25 DEGs in the other mouse models. Therefore, counts of
DEGs increased progressively with age in B6.Q111 and CD1.Q111 mice, while few DEGs could be detected in the other
mouse models.
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Figure 2. Age- and strain-dependent effects of Htt alleles on gene expression. (A) Counts of up- and down-regulated genes (FDR q < 0.05) in each genotype at three time
windows: ‘early’ (4- to 9-week-old), ‘middle’ (9- to 16-week-old), and ‘late’ (16- to 20-week-old). (B) Overlap between differentially expressed genes (DEGs) detected in
the three conditions with >25 DEGs. (C) Overlap between DEGs in 16- to 20-week-old B6.Q111 mice (this study) and DEGs in 6-month-old B6.Q111 mice from Langfelder
et al. (2016). (D) Overlap between DEGs in 16- to 20-week-old B6.Q111 mice (this study) and DEGs in post-mortem caudate nucleus from HD cases vs. controls (Hodges
et al. 2006).

Replication of DEGs across conditions and in
independent datasets
There was extensive overlap between the DEGs identified in different age x genotype conditions (Fig. 2B). 178 of the 222 DEGs in
16- to 20-week-old CD-1.Q111 mice (80%) were also differentially
expressed in 16- to 20-week-old B6.Q111 mice (Fisher’s exact
test: P ¼ 1.4e-173). 198 of the 279 DEGs in 9- to 16-week-old
B6.Q111 mice were also differentially expressed in 16- to 20week-old B6.Q111 mice (P ¼ 1.0e-174). 77 DEGs were shared
among all three conditions with > 25 DEGs.
There was also extensive overlap between the DEGs identified in our study and striatal gene expression changes in independent datasets from HD knock-in mouse models and human
postmortem brain. 726 of the DEGs in 16- to 20-week-old
B6.Q111 mice were differentially expressed in striata of 6month-old B6.Q111 mice profiled by RNA-seq (16) (P < 2.2e-308;
Fig. 2C). 761 of the DEGs in 16- to 20-week-old B6.Q111 mice
were differentially expressed in post-mortem striatal tissue
from (human) HD cases vs. controls (Hodges et al. 2006; P ¼ 3.1e14; Fig. 2D). Notably, there were far fewer DEGs in the <20-weekold mice from our study than in the older mice profiled by
Langfelder et al. (16) and in post-mortem human striatum.
These results suggest that the DEGs identified in our study represent a robust transcriptomic signature for the early effects of
the HD mutation in the striatum.

Differentially expressed genes are involved in diverse
neuronal functions
We used Gene Ontology (30) and Cell-type Specific Expression
Analysis (31,32) to characterize biological functions enriched for
DEGs in 16- to 20-week-old B6.Q111 vs. WT mice and the dominant cell types in which they are expressed. Down-regulated

genes were enriched for genes that are expressed specifically in
Drd1- and Drd2-positive medium spiny neurons (P ¼ 7.4e-53,
P ¼ 9.6e-44, respectively; Supplementary Material, Table S4).
Down-regulated genes were enriched for 389 Gene Ontology
terms (FDR < 0.05; Supplementary Material, Table S5). Many of
the most strongly enriched pathways relate to synaptic activity,
such as ‘dopamine receptor signaling pathway’ (P ¼ 1.0e-14),
‘regulation of membrane potential’ (P ¼ 1.9e-19), ‘regulation of
ion transport’ (5.0e-19), ‘neuron projection morphogenesis’
(P ¼ 3.4e ¼ 18), and ‘ionotropic glutamate receptor binding’ (P ¼ 1.
4e-12). Down-regulated genes were also enriched for components of intracellular signaling pathways known for their roles
in coupling the activity of transmembrane receptors to downstream cellular processes. These pathways included ‘regulation
of G-protein-coupled receptor protein signaling pathway’ (P ¼ 2.
9e-22), ‘calmodulin binding’ (P ¼ 1.3e-25), ‘GTPase activator activity’ (P ¼ 1.3e-20), ‘response to organic cyclic compound’ (P ¼ 3.
4e-14), and ‘response to insulin’ (P ¼ 2.7e-11).
Up-regulated genes in 16- to 20-week-old B6.Q111 mice were
not strongly enriched for cell type-specific genes, suggesting
that these expression changes are distributed across multiple
cell types (Supplementary Material, Table S4). These genes were
enriched for 188 pathways (FDR < 0.05; Supplementary Material,
Table S6). Like down-regulated genes, up-regulated genes were
enriched for neuronal functions, such as ‘neuron projection
morphogenesis’ (P ¼ 3.2e-13). In addition, up-regulated genes
were enriched for more general cellular functions, such as
‘translation’ (P ¼ 5.3e-13), ‘ubiquitin protein-ligase binding’
(P ¼ 8.2e-9), and ‘regulation of homeostatic process’ (P ¼ 4.7e-10).
These results indicate that the Htt CAG expansion influences
the expression of genes with diverse functions, even early in
the pathogenic process.
Notably, we found few expression changes in genes related to
neuroinflammation, astrogliosis, and apoptosis (Supplementary

Human Molecular Genetics, 2017, Vol. 26, No. 5

Materials, Tables S5 and S6). All of these processes are upregulated in striatal tissue from HD mouse models sampled later in
life and in post-mortem tissue from HD patients (14,16).
Therefore, our results suggest that neuroinflammation-related
transcriptomic changes are secondary to the ‘neuronal’ signature
detected in the young mice from our study.

Gene expression changes in 4- to 16-week-old HD
knock-in mice
The results above suggest that robust HD-related gene expression
changes occur in 16- to 20-week-old B6.Q111 and CD-1.Q111 mice.
We next asked whether we could detect early signs of this HD
molecular signature in even younger mice and in other mouse
strains. Although we detected few DEGs in these conditions, we
hypothesized that younger mice and/or those with lower CAG
lengths might show subtle changes in expression that would be
correlated with the expression changes detected at later stages of
the phenotypic progression. To test this hypothesis, we focused
on the expression patterns of the top 100 genes with the lowest
P-values in 16- to 20-week-old B6.Q111 mice (Fig. 3). Many of
these genes—e.g. Pde10a, Penk, Cnr1, and Gpx6—are differentially
expressed in striatal tissue from HD patients (14) and in previous
studies of HD knock-in mouse models (16).
We fit a linear model to test whether the fold changes of
these top 100 genes predicted their fold changes in other conditions. That is, we asked to what extent the direction and magnitude of the fold changes were consistent across mouse models
and time points. In this model, the correlation coefficient (r) describes the strength of the linear relationship between the fold
changes of the top 100 genes in each pair of conditions, while
the regression coefficient (b1) describes the relative sizes of the
fold changes.
In 16- to 20-week-old mice, the fold changes of the top 100
genes were positively correlated between B6.Q111 mice and
each of the other genetic models (Fig. 4; r ¼ 0.38—0.97). The fold
changes varied between strains, with the largest fold changes in
B6.Q111, followed by CD-1.Q111 (b1 ¼ 0.62, relative to 16- to 20week-old B6.Q111 mice), FVB.Q111 (b1 ¼ 0.43), B6.Q92 (b1 ¼ 0.25),
129.Q111 (b1 ¼ 0.20) and B6.Q50 (b1 ¼ 0.07).
In 9- to 16-week-old mice, the fold changes of the top 100
genes were positively correlated in B6.Q111, CD-1.Q111,
FVB.Q111, and B6.Q92 mice (r ¼ 0.34—0.96) but were not correlated in 129.Q111 or B6.Q50 mice. B6.Q111 mice had the largest
fold changes (b1 ¼ 0.58), followed by CD-1.Q111 (b1 ¼ 0.38),
FVB.Q111 (b1 ¼ 0.18), B6.Q92 (b1 ¼ 0.06).
In 4- to 9-week-old mice, fold changes were more variable.
Fold changes were positively correlated in B6.Q111 (r ¼ 0.72,
b1 ¼ 0.17), FVB.Q111 (r ¼ 0.44, b1 ¼ 0.08), and 129.Q111 (r ¼ 0.57,
b1 ¼ 0.15), compared to 16- to 20-week-old B6.Q111 mice.
However, fold changes were negatively correlated in B6.Q92
mice of this age (r ¼ 0.41, b1 ¼ 0.11), and were uncorrelated in
CD-1.Q111 and B6.Q50 mice. These results suggest that HD mutations influence many of the same genes across multiple
mouse models of the HD mutation, but genetic background and
CAG repeat length influence the rate at which these genes become differentially expressed.

Multiple molecular and genetic mechanisms may
underlie strain differences in response to HD mutations
Our results show that both CAG repeat length and strain genetic
background modify the rate at which molecular and cellular
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phenotypes progress in mice with Htt CAG expansions.
Phenotypic variation may be driven at least in part by the different inherited CAG repeat lengths in each of the four Q111
strains (Fig. 1B), but is not explained by variation in Htt expression (Supplementary Material, Fig. S1). As the strains also exhibit differences in the rate of somatic CAG expansion (Fig. 1E)
we hypothesized that these strain differences involve a known
genetic polymorphism that influences somatic instability of the
CAG repeat in B6.Q111 vs. 129.Q111 mice. A previously reported
genetic mapping study in C57BL/6N.Q111 x 129.Q111 mice
showed that variants at the Mlh1 locus were linked to slower Htt
CAG somatic expansion in the striata of 129.Q111 vs. B6N.Q111
mice (29). These variants were associated with lower expression
of the Mlh1 gene, which encodes a mismatch repair enzyme,
MutL homolog 1. We examined Mlh1 expression in mice from
each of the four background strains in our study to replicate the
previously reported expression polymorphism in B6N or B6J vs.
129 mice (29) and to assess differences in CD-1 and FVB mice.
Wildtype 129 mice had 2.8-fold lower expression of Mlh1, compared to wildtype B6 mice, consistent with previous findings
(Fig. 5), while B6, CD-1 and FVB mice all had similar high expression of Mlh1. The intermediate rates of somatic CAG expansion
in FVB and CD-1 strains are consistent with high Mlh1 expression in these strains, but suggest additional modifier genes(s)
that might reduce expansion relative to B6. Nuclear mutant
huntingtin immunostaining phenotypes correlate reasonably
well with the rates of somatic CAG expansion across strain
background, indicating that genetic modifiers of these Htt CAGdependent events may be shared. Notably, however, the very
different transcriptional responses to the Q111 allele in B6, FVB
and CD-1 strains are unlikely to be explained by genetically
encoded changes in Mlh1 expression. Overall, these results indicate that multiple genetic factors may modify responses to the
HD mutation.

Discussion
The cascade of early molecular, cellular and transcriptional
changes that occurs as a result of CAG expansion in HD mouse
models has not previously been studied systematically across a
week-by-week timescale. We generated transcriptomic data in
a dense time-series from the striatum of mice with Htt CAG repeat expansions in parallel with molecular and cellular phenotyping to elucidate the timing and magnitude of CAG lengthand age-dependent changes across four genetic background
strains. We observed robust striatal CAG length expansion,
mHTT nuclear localization, and gene expression changes in
B6.Q111 mice as young as 9- to 16-week old. We find evidence
that subtle changes in these same phenotypes begin to manifest
even earlier in life and with shorter CAG repeat tracts. While
the Q111 allele induced similar molecular changes on the other
background strains studied, the rate of progression differed
across these strains. Our study provides a dense and dynamic
view of very early phenotypic and transcriptomic changes in
the striatum of mice with Htt CAG repeat expansions.
Our results reveal very early gene expression changes in the
striatum of Q111 mice. Most of these expression changes were
very small, typically less than 1.5-fold differences in expression
in 16- to 20-week-old B6.Q111 vs. WT mice. These effect sizes in
our analysis of bulk striatal tissue are consistent either with
subtle changes occurring in many striatal cells or with more
dramatic changes occurring in a small subset of striatal cells.
Many of the differentially expressed genes are involved in
synaptic functions and are predominantly expressed in neurons
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Figure 3. Expression patterns of the top 100 differentially expressed genes. The top 100 genes were defined by their P-values in 16- to 20-week-old B6.Q111 mice. The
heatmap indicates the -log10(P-values) of these genes in 18 conditions defined by genotype and age window. Orange gradient ¼ up-regulated in Q111; blue gradient ¼
down-regulated in Q111; color range, -7 < z-score <7.

rather than glia. Most of these same pathways are also differentially expressed in older mice with HD mutations and in postmortem striatal tissue from HD cases vs. controls. Notably,
however, the biological processes perturbed in young Q111 mice
represent only a small fraction of processes that are perturbed
later in the disease. For instance, in contrast to studies of 6- and
10-month-old B6.Q111 mice, we find a few changes in genes associated with neuroinflammation and activated gliosis (16).
Therefore, our results suggest that the sequence of molecular
changes associated with HD mutations begins with a relatively
small number of changes in neurons, before cascading onward
to broader pathology in both neurons and in glia.
Our results suggest that multiple genetic modifiers influence
the effects of the Q111 allele on molecular phenotypes. B6 mice
consistently presented the most rapid phenotypic progression
while 129 mice were the slowest. These phenotypic differences
appear to be primarily quantitative and not qualitative: i.e. we
observed correlated gene expression responses in all strains,
but the rate of change differed. Our study was not specifically
designed to detect potential modifier effects of strain

background, but rather to identify robust gene expression
changes across multiple strains. Thus, the relatively low CAG
repeat length in 129.Q111 mice could, at least in part, contribute
to the slower phenotypic progression in this strain. However,
the slow rates of the transcriptional responses in CD-1 and FVB
compared to B6, despite having similar or longer CAG repeat
lengths than B6, indicates the presence of modifier genes.
Further, an expression QTL at the Mlh1 locus that is linked to
differences in Htt CAG length expansion in B6 vs. 129 mice do
not appear to explain strain differences in CD-1 and FVB relative
to B6, suggesting that other genetic modifiers of the transcriptional response are present in these strains. Further unbiased
identification of the genetic modifiers of different phenotypes in
Htt CAG knock-in mice, e.g. by crossing mice with HD mutations
onto a mapping population such as the Collaborative Cross or
Mouse Diversity outbred collection (33,34), is a promising future
direction that could reveal multiple modifier loci. Identifying
these genetic modifiers could point to novel therapeutic targets.
The proximal mechanisms by which HD mutations cause
early gene expression changes remain unclear. Several non-
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Figure 5. Effects of genetic background and of HD mutations on Mlh1 expression.
Box plots represent mean expression of Mlh1 in each strain and genotype group.

through changes in chromatin or regulatory states (39–41); (iii)
gene expression changes are secondary or occur indirectly as a
result of another mechanism. In our study, we found that the
rates of somatic Htt CAG length expansion, mHTT nuclear localization, and transcriptional changes were all correlated with
age. These correlations suggest that these phenotypes are connected but make it difficult to distinguish causal from correlative relationships. Unbiased genetic studies to determine
whether common or different modifiers underlie these phenotypes will help to disentangle these relationships. More detailed
biochemical experiments will be required to identify a subset of
the observed changes that are caused by direct interactions
with huntingtin protein.
Since the 1993 discovery of the HD mutation, research into
the causal mechanism underlying neurodegeneration has generally focused on late stage disease. However, a wide range of pathophysiology is present in late stages of HD, much of which may
be only peripherally related to pathogenesis. Our approach focuses instead on studying earlier, more subtle perturbations, enabling us to identify a smaller number of candidate mechanisms.
By measuring transcriptomic, molecular, and cellular changes
with many samples across a dense time series we were able to
precisely time inflection points such as gene expression changes
and nuclear mHTT phenotypes. Equally critical is our observation
of striking differences in the magnitude and timing of these effects across strains. This study contributes to the burgeoning field
of ‘pre-manifest’ HD research, clarifying molecular changes that
occur well before the onset of diagnosable clinical symptoms
with the potential of proffering new therapeutic targets.

Methods
Breeding
Figure 4. Age, CAG length and genetic background influences the magnitude but
not the direction of gene expression changes in HD knock-in mice. Each scatterplot compares the fold changes of the top 100 genes in 16- to 20-week-old
B6.Q111 mice (x-axis) to the fold changes of these genes in another condition,
defined by age and genotype (y-axis). Each point on the scatterplot indicates the
fold change estimate of a single gene.

mutually-exclusive mechanisms have been proposed (35–38): (i)
Both wildtype and mutant HTT form protein complexes with
transcription factors, and these interactions could change the
ability of these TFs to regulate their target genes; (ii) direct interaction of huntingtin protein with chromatin modifying enzymes and with genomic DNA influences gene expression

Heterozygous males of six different strains (129S2/
SvPasCrl.HttQ111/þ, FVB/NCrl.HttQ111/þ, CD-1.HttQ111/þ, C57BL/
6J.HttQ92/þ, C57BL/6J.HttQ50/þ, C57BL/6J.HttQ111/þ) were crossed
with wild type females of corresponding background strains in
order to generate cohorts of age-matched heterozygous pups
and WT controls for the time-course assigned tissue harvests.
We also generated through the same breeding scheme mice
heterozygous for the CD-1. HttneoQ50/þ allele and their wildtype
littermates. Transcriptomic data that were generated from
these mice are available in GEO (GSE88920) but were not analyzed as part of this study as the presence of the neo-resistance
gene renders this allele hypomorphic (25). A tail snip was
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acquired at pre-weaning (2–4 weeks) to determine the CAG repeat length of each mouse.
One heterozygous animal and one age-matched wild type
control animal from each strain were harvested three times
weekly from 4 to 20 weeks of age. The sex of mice harvested at
these times was randomized. An additional 5 female and 5 male
heterozygous animals from the B6.Q50, B6.Q111 and CD1.Q111
strains were harvested at 4, 8, 12, 16, and 20 weeks of age. Time
of day of harvest was randomized within the hours of light in
the mouse room, typically 3 hours after lights came on
and 3 hours before lights went off.
Euthanasia was performed using live decapitation. Trunk
blood was collected and plasma was frozen and stored at
80  C. The right hemisphere of each animal’s brain was microdissected into thalamus, cortex, striatum, hippocampus, and remaining brain regions. These tissues were snap frozen and
stored at 80  C. The left hemisphere was embedded in OCT
embedding medium, snap frozen, and stored at 80  C for sectioning. Snap-frozen striata from the right hemisphere of each
animal were used for isolation of RNA and DNA for transcriptional profiling and analyses of CAG instability, and sectioned
tissue from the left hemisphere was used for immunostaining
with mAb5374.

mAb5374 immunofluorescence
Nuclear mutant huntingtin localization was assessed by immunofluorescence imaging of frozen 7 lm coronal sections with
the mAb5374 antibody (Chemicon), as previously described (42).
The mAb5374 antibody is a conformationally sensitive antibody
that detects diffusely immunostaining nuclear mutant huntingtin and intranuclear inclusions. We used Cell Profiler image
analysis software (43) to quantify the intensity of nuclear
mAb5374 staining in each cell. The max intensity in each cell
was normalized to intensity levels in wild type animals to calculate a normalized score.

striatum is reflected in a broader distribution of alleles, strongly
biased to longer CAG lengths.

Microarray gene expression profiling
RNA was extracted from the striata of individual mice using
Trizol reagent (DNA was isolated for instability analyses in the
same procedure). We profiled gene expression on SurePrint G3
8x60k Mouse Microarrays (Agilent, Santa Clara, CA). We performed quantile normalization and log2-transformation. We
used ComBat (45) to remove batch effects related to the date on
which microarrays were hybridized. Linear models were fit using the limma R package (46). Age was treated as a categorical
variable with three classes: ‘early’, 4- to 9-week-old; ‘middle’, 9to 16-week-old; ‘late’, 16- to 20-week-old. We considered the
nominal Htt allele as a categorical variable. We fit a linear model
to predict each gene’s expression, considering the effects of
background strain, age, sex, and Htt allele. We used post-hoc
contrasts to evaluate the effects of Htt allele in each background
strain x age condition. A false discovery rate for these P-values
was calculated using the Benjamini-Hochberg method (47). We
note that multiple widely accepted methods are available to
analyze microarray data, and lists of differentially expressed
genes would inevitably differ to some extent depending on the
choice of method. This dataset has been deposited in GEO, accession GSE88920. Scripts and processed data have also been
deposited in a GitHub repository located at https://github.com/
seth-ament/hd-time-series.

Supplementary Material
Supplementary Material is available at HMG online.
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